2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Immunology, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3635 Clinical phenotype, cell of origin, and diagnostic approach as determinants of outcome in primary and secondary central nervous system lymphoma: A single-institution experience

Arvind Sivashanmugam, MD, Ross S Terada, DO2, Adam J. Olszewski, MD3, Thomas Ollila, MD4
1 Brown University Warren Alpert School of Medicine, Providence, Rhode Island, United States
2 Brown University Warren Alpert School of Medicine, Providence, Rhode Island, United States
3 Brown University Warren Alpert School of Medicine, Providence, Rhode Island, United States
4 Brown University Warren Alpert School of Medicine, Providence, Rhode Island, United States

Background: Central nervous system (CNS) lymphoma has substantial variability in clinical presentation, diagnostic pathways, and clinical outcomes. Due to the rarity of the condition and heterogeneity of affected patients, many questions regarding the upfront management of CNS lymphoma remain unanswered. For example, while surgical resection has historically not had a role in treatment of CNS lymphoma, recent data have questioned this approach. A meta-analysis of retrospective trials reported an association between overall survival (OS) and extent of resection, but resection was also associated with solitary and superficial lesions, which are likely confounding factors (Chojak et al., 2022). Additionally, the impact of cell of origin remains an area of investigation. While germinal center origin is known to be a risk factor for CNS relapse, the phenotype of relapse and impact on management are unknown. Here, we characterize a cohort of CNS lymphoma patients, evaluating the impact of surgical resection and cell-of-origin classification.     

Methods: We describe preliminary outcomes from 100 CNS lymphoma patients from two New England medical centers in a shared institutional system. Patients with primary and secondary lymphoma were identified by their treating physician and retrospectively analyzed. Cell of origin was classified as a germinal center B-cell (GCB) or non-GCB per Hans algorithm. Clinical presentation was categorized as parenchymal, dural, leptomeningeal-only, and ocular. Outcomes assessed included complete response (CR), progression-free survival (PFS), and overall survival (OS).     

Results: In the primary CNS lymphoma cohort (n=56), 35.2% were of GCB cell of origin, 37.0% were non-GCB, and 27.8% were unidentified due to incomplete immunohistochemistry data. In the secondary CNS lymphoma cohort (n=44), 35.2% were GCB, 36.4% were non-GCB, and 28.4% were unidentified due to incomplete immunohistochemistry data. Primary CNS lymphoma patients undergoing resection (n=5) were hospitalized for an average of 15 days compared to an average of 7 days for patients who underwent stereotactic or open biopsy (n=43) (p=0.037). Time from diagnosis to treatment was longer in patients who underwent resection (12 days) than biopsy (6.5 days), although the difference was not statistically significant (p=0.26). There was no significant difference in PFS (p=0.88) or OS (p=0.63) between patients undergoing resection and those undergoing biopsy. In the combined cohort, GCB status (n=35) was associated with a mean PFS of 18.8 months and a mean OS of 23.3 months. Non-GCB status (n=39) was associated with a mean PFS of 28.5 months and a mean OS of 35.2 months. Of patients with GCB cell of origin, 74.3% exhibited parenchymal CNS disease, 5.7% exhibited dural or ocular disease, and 20% exhibited leptomeningeal-only CNS disease. Of patients with non-GCB cell of origin, 76.9% exhibited parenchymal CNS disease, 12.8% dural or ocular disease, and 10.3% leptomeningeal-only CNS disease. In patients exhibiting parenchymal disease (n=76), the CR rate was 35.5% with a mean PFS of 26.7 months and mean OS of 33.0 months. In leptomeningeal-only disease (n=13), the CR rate was 23.1% with a mean PFS of 11.3 months and mean OS of 14.2 months. In dural or ocular disease (n=12), the CR rate was 23.1% with a mean PFS of 30.7 months and mean OS of 37.2 months.   

Conclusions: In our single-institution cohort of CNS lymphoma patients, upfront surgical resection of CNS disease was associated with prolonged length of stay without improvements in PFS or OS, suggesting that additional studies are needed to contextualize the role of resection in this disease. Additionally, GCB cell of origin was identified in approximately one-third of patients in both primary and secondary CNS lymphoma, suggesting a more balanced distribution in contrast to prior data indicating the vast majority of primary CNS lymphoma is of germinal center origin (Woo et al., 2022). Germinal center origin may be associated with unfavorable prognosis but not with a particular clinical phenotype. These findings underscore the need for larger, prospective studies to characterize the clinical heterogeneity of CNS lymphoma and guide management decisions.   

Arvind Sivashanmugam, MD: No relevant conflicts of interest to declare.